TY - JOUR
T1 - Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents
T2 - Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency
AU - Drug and Therapeutics Committee
AU - Ethics Committee of the Pediatric Endocrine Society
AU - Grimberg, Adda
AU - DiVall, Sara A.
AU - Polychronakos, Constantin
AU - Allen, David B.
AU - Cohen, Laurie E.
AU - Quintos, Jose Bernardo
AU - Rossi, Wilma C.
AU - Feudtner, Chris
AU - Murad, Mohammad Hassan
N1 - Publisher Copyright:
© 2016 S. Karger AG, Basel. Copyright: All rights reserved.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background/Aims: On behalf of the Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society, we sought to update the guidelines published in 2003 on the use of growth hormone (GH). Because idiopathic short stature (ISS) remains a controversial indication, and diagnostic challenges often blur the distinction between ISS, GH deficiency (GHD), and primary IGF-I deficiency (PIGFD), we focused on these three diagnoses, thereby adding recombinant IGF-I therapy to the GH guidelines for the first time. Methods: This guideline was developed following the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation). Results: This guideline provides recommendations for the clinical management of children and adolescents with growth failure from GHD, ISS, or PIGFD using the best available evidence. Conclusion: The taskforce suggests that the recommendations be applied in clinical practice with consideration of the evolving literature and the risks and benefits to each individual patient. In many instances, careful review highlights areas that need further research.
AB - Background/Aims: On behalf of the Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society, we sought to update the guidelines published in 2003 on the use of growth hormone (GH). Because idiopathic short stature (ISS) remains a controversial indication, and diagnostic challenges often blur the distinction between ISS, GH deficiency (GHD), and primary IGF-I deficiency (PIGFD), we focused on these three diagnoses, thereby adding recombinant IGF-I therapy to the GH guidelines for the first time. Methods: This guideline was developed following the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation). Results: This guideline provides recommendations for the clinical management of children and adolescents with growth failure from GHD, ISS, or PIGFD using the best available evidence. Conclusion: The taskforce suggests that the recommendations be applied in clinical practice with consideration of the evolving literature and the risks and benefits to each individual patient. In many instances, careful review highlights areas that need further research.
KW - Children
KW - Growth hormone
KW - Guidelines
KW - Insulin-like growth factor-I
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85000879016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85000879016&partnerID=8YFLogxK
U2 - 10.1159/000452150
DO - 10.1159/000452150
M3 - Article
C2 - 27884013
AN - SCOPUS:85000879016
SN - 1663-2818
VL - 86
SP - 361
EP - 397
JO - Hormone Research in Paediatrics
JF - Hormone Research in Paediatrics
IS - 6
ER -